Most Effective Symptomatic Treatment for Rhinorrhoea in Common Cold
Intranasal ipratropium bromide 0.06% is the most effective treatment specifically for rhinorrhoea associated with the common cold, reducing nasal discharge by 26-34% compared to placebo. 1, 2
Primary Recommendation: Ipratropium Bromide
Ipratropium bromide nasal spray 0.06% is FDA-approved for patients ≥5 years of age specifically for rhinorrhoea caused by the common cold. This anticholinergic agent works by blocking parasympathetic stimulation that drives glandular secretion during viral upper respiratory infections 1.
Evidence Supporting Ipratropium:
- Reduces nasal discharge by 26% compared to control spray and 34% compared to no treatment (P < 0.01) 3
- Decreases subjective rhinorrhoea severity by 31% versus controls and 78% versus untreated patients (P = 0.0001) 3
- Level 1a evidence confirms effectiveness specifically for ameliorating rhinorrhoea 2, 4
- Works locally on nasal mucosa with minimal systemic absorption 1
Dosing and Administration:
- Two 42-microgram sprays per nostril, 3-4 times daily during waking hours
- Most effective when started within 36 hours of symptom onset
- Treatment duration: typically 4 days 3
Important Caveats:
- Does NOT improve nasal congestion - this is critical to understand 1, 2, 4
- Common side effects include epistaxis (blood-tinged mucus in 16.8% vs 3.6% placebo) and nasal dryness (11.7% vs 3.6% placebo), but these are well-tolerated and self-limiting 1, 3
- Does not alter normal nasal functions (smell, ciliary clearance) 1
Alternative Options (When Combination Therapy Needed)
First-Generation Antihistamine/Decongestant Combinations:
If treating multiple symptoms beyond just rhinorrhoea, consider brompheniramine with sustained-release pseudoephedrine 5, 6. This combination has Grade A evidence for reducing rhinorrhoea, sneezing, and nasal congestion together.
- Brompheniramine reduces nasal secretion weights significantly (4.3g vs 6.8g on day 1, P < 0.03) 6
- Also decreases sneeze counts by approximately 50% 6
- Warning: Causes somnolence and should not be used in young children 2, 5
What Does NOT Work:
The 2020 European Position Paper provides clear guidance on ineffective treatments 2:
- Intranasal corticosteroids: No evidence for symptomatic relief in common cold (Level 1a negative evidence)
- Second-generation antihistamines: Limited benefit only on days 1-2, no clinically significant effect on rhinorrhoea specifically 2
- Antibiotics: No benefit and cause significant adverse effects 2
Practical Algorithm for Rhinorrhoea Treatment:
Isolated rhinorrhoea as primary complaint → Ipratropium bromide 0.06% nasal spray
Rhinorrhoea + nasal congestion → Add oral decongestant (pseudoephedrine) OR use first-generation antihistamine/decongestant combination
Can combine ipratropium with antihistamines for increased efficacy without increased adverse events 1
Ipratropium + intranasal corticosteroid is more effective than either alone for rhinorrhoea in allergic/nonallergic rhinitis, but this combination is NOT indicated for common cold 1
Additional Supportive Measures:
While not as effective as ipratropium for rhinorrhoea specifically:
- Nasal saline irrigation: Possible benefits, especially in children 2
- Zinc lozenges (≥75 mg/day within 24 hours of onset): Reduces overall cold duration 2
- Vitamin C: May reduce duration/severity on individual basis 2
Key Clinical Pitfall to Avoid:
Do not prescribe ipratropium expecting improvement in nasal congestion - it is approved ONLY for rhinorrhoea treatment 1. If congestion is a significant complaint, you must add a separate decongestant or use combination therapy from the start.